Trial reportFrontiers in immunology2021
Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections.
Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Dengue fever diagnosis in resource-limited settings.Epidemiology and infection · 2025Review
- Comparison of the sensitivity and specificity of commercial anti-dengue virus IgG tests to identify persons eligible for dengue vaccination.Journal of clinical microbiology · 2024Article
- Comparison of the Sensitivity and Specificity of Commercial Anti-Dengue Virus IgG Tests to Identify Persons Eligible for Dengue Vaccination.medRxiv : the preprint server for health sciences · 2024Article
- Validity of Self-Reported Mosquito Bites to Assess Household Mosquito Abundance in Six Communities of Esmeraldas Province, Ecuador.The American journal of tropical medicine and hygiene · 2023Article
- Is new dengue vaccine efficacy data a relief or cause for concern?NPJ vaccines · 2023Review
- Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines.Frontiers in immunology · 2023Article
- Field evaluation of rapid diagnostic tests to determine dengue serostatus in Timor-Leste.PLoS neglected tropical diseases · 2022Article
- Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.Microbiology spectrum · 2022Article
- Peptide Biomarkers for the Diagnosis of Dengue Infection.Frontiers in immunology · 2022Article
- Componential usage patterns in dengue 4 viruses reveal their better evolutionary adaptation to humans.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 11 institutions in 3 countries.
Fernando EchegarayViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Peter LaingExcivion Ltd., Cambridge, United Kingdom.
Samantha HernandezDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Sully MarquezInstituto de Microbiología, Universidad San Francisco de Quito, Quito, Ecuador.
Amanda HarrisExcivion Ltd., Cambridge, United Kingdom.
Ian LaingExcivion Ltd., Cambridge, United Kingdom.
Adam ChambersOxford Expression Technologies Ltd., Oxford, United Kingdom.
Neil McLennanGlobalDX Ltd., Mensrie, United Kingdom.
Victor A SugihartoViral & Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD, United States.
Hua-Wei ChenViral & Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD, United States.
Sandra Vivero VillagranInstituto de Investigación en Biomedicina (Inbiomed), Universidad Central, Quito, Ecuador.
Abigail CollingwoodDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, United States.
Magelda MontoyaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Fausto Bustos CarrilloDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Mark P SimonsViral & Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD, United States.
Philip J CooperDepartment of Infection and Immunity, St George's University of London, London, United Kingdom.
Andrea LopezSchool of Medicine, Universidad International del Ecuador, Quito, Ecuador.
Gabriel TruebaInstituto de Microbiología, Universidad San Francisco de Quito, Quito, Ecuador.
Joseph EisenbergDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, United States.
Shuenn-Jue WuViral & Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD, United States.
William MesserDepartment of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, OR, United States.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Josefina ColomaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Leah C KatzelnickViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
University of California, Berkeley · USNaval Medical Research Command · USExcivion (United Kingdom) · GBNational Institutes of Health · USUniversidad San Francisco de Quito · ECUniversity of Michigan–Ann Arbor · USCentral University of Ecuador · ECOregon Health & Science University · USOxford Technologies (United Kingdom) · GBSt George's, University of London · GBUniversidad Internacional del Ecuador · EC
Funding
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Aravinda M. DeSilva · 2015 to 2026
$34.1MOregon Clinical and Translational Research InstituteUL1TR000128 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$28.7MResearch Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5MAmerican Asian Centers for Arbovirus Research and Enhanced Surveillance (A2CARES)U01AI151788 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Josefina Coloma, Eva Harris · 2020 to 2026
$9.6MImmunology, virology, and epidemiology of flaviviruses and other emerging virusesZIAAI001346 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KATZELNICK, LEAH · 2021 to 2025
$7.1MLiving in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease riskU01AI153416 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI HARRIS, EVA · 2021 to 2025
$4.9MZika and Dengue Co-circulation Under Environmental Change and UrbanizationR01AI132372 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLOMA, JOSEFINA, EISENBERG, JOSEPH N. S. · 2017 to 2020
$2.9MEpidemiological, Clinical & Immunological Studies of Zika, dengue and chikungunyaR01AI099631 · NIAID · SUSTAINABLE SCIENCES INSTITUTE · PI BALMASEDA, ANGEL LAZARO · 2012 to 2021
$1.8MDengue virus immunity in endemic and non-endemic human cohortsR21AI135537 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI MESSER, WILLIAM · 2018 to 2019
$439kFIC NIH HHS D43 TW010540NCATS NIH HHS UL1 TR000128NIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI099631NIAID NIH HHS R01 AI132372NIAID NIH HHS R21 AI135537NIAID NIH HHS U01 AI151788NIAID NIH HHS U01 AI153416
Abstract
The only licensed dengue vaccine, Dengvaxia
Indexed as
DengueDiagnostic Tests, RoutineAdolescentAdultAgedAged, 80 and overAntibodies, ViralChildChild, PreschoolDengue VaccinesDengue VirusFemaleHumansImmunoglobulin GImmunoglobulin MInfantAntibodies, ViralDengue VaccinesImmunoglobulin GImmunoglobulin Mdenguedengue vaccinepre-vaccination screeningrapid diagnostic testZika
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.